EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis

Cong Liu iD, Milena Schönke, Borah Spoorenberg, Joost M Lambooij, Hendrik J P van der Zande, Enchen Zhou iD, Maarten E Tushuizen, Anne-Christine Andreasson iD, Andrew Park, Stephanie Oldham, Martin Uhrbom, Ingela Ahlstedt und 7 weitere

eLife · 17.01.2023 · 12

DOI: 10.7554/elife.83075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 17.01.2023. Verfasst von Cong Liu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, Netherlands. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Diabetes Fonds, Netherlands Organisation for Scientific Research, Chinese Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Analogues of the hepatokine fibroblast growth factor 21 (FGF21) are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and insulin-sensitizing effects have been largely unraveled, the mechanisms by which they alleviate liver injury have only been scarcely addressed. Here, we aimed to unveil the mechanisms underlying the protective effects of FGF21 on NASH using APOE*3-Leiden.CETP mice, a well-established model for human-like metabolic diseases. Liver-specific FGF21 overexpression was achieved in mice, followed by administration of a high-fat high-cholesterol diet for 23 weeks. FGF21 prevented hepatic lipotoxicity, accompanied by activation of thermogenic tissues and attenuation of adipose tissue inflammation, improvement of hyperglycemia and hypertriglyceridemia, and upregulation of hepatic programs involved in fatty acid oxidation and cholesterol removal. Furthermore, FGF21 inhibited hepatic inflammation, as evidenced by reduced Kupffer cell (KC) activation, diminished monocyte infiltration, and lowered accumulation of monocyte-derived macrophages. Moreover, FGF21 decreased lipid- and scar-associated macrophages, which correlated with less hepatic fibrosis as demonstrated by reduced collagen accumulation. Collectively, hepatic FGF21 overexpression limits hepatic lipotoxicity, inflammation, and fibrogenesis. Mechanistically, FGF21 blocks hepatic lipid influx and accumulation through combined endocrine and autocrine signaling, respectively, which prevents KC activation and lowers the presence of lipid- and scar-associated macrophages to inhibit fibrogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2MiceHumansAnimalsMacrophage ActivationCicatrixLiverInflammationDiet, High-FatCholesterolLipidsMice, Inbred C57BLDisease Models, AnimalFibroblast Growth Factors

Stichwörter der Autor:innen

fibroblast growth factor 21immunologyinflammationlipid/scar-associated macrophagesliver-adipose tissue crosstalkmedicinemousesteatohepatitis

Substanzen

CholesterolLipidsfibroblast growth factor 21Fibroblast Growth Factors

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, Netherlands.
  • Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, Netherlands.
  • Department of Parasitology, Leiden University Medical Center, Leiden, Netherlands.
  • Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands.
  • Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, Netherlands.
  • Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Cong Liu, Enchen Zhou, Anne-Christine Andreasson, Kristina Wallenius, Patrick C N Rensen

Förderung

  • Diabetes Fonds
  • Netherlands Organisation for Scientific Research
  • Chinese Scholarship Council
  • Novo Nordisk Foundation
  • Hartstichting

Zitieren

APA

Liu, C., Schönke, M., Spoorenberg, B., Lambooij, J. M., van der Zande, H. J. P., Zhou, E., Tushuizen, M. E., Andreasson, A. C., Park, A., Oldham, S., Uhrbom, M., Ahlstedt, I., Ikeda, Y., Wallenius, K., Peng, X. R., Guigas, B., Boon, M. R., Wang, Y., & Rensen, P. C. N. (2023). FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. eLife, 12. https://doi.org/10.7554/elife.83075

Vancouver

Liu C, Schönke M, Spoorenberg B, Lambooij JM, van der Zande HJP, Zhou E, et al. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. eLife. 2023;12. doi:10.7554/elife.83075

BibTeX
@article{Liu2023,
  author = {Liu, Cong and Schönke, Milena and Spoorenberg, Borah and Lambooij, Joost M and van der Zande, Hendrik J P and Zhou, Enchen and Tushuizen, Maarten E and Andreasson, Anne-Christine and Park, Andrew and Oldham, Stephanie and Uhrbom, Martin and Ahlstedt, Ingela and Ikeda, Yasuhiro and Wallenius, Kristina and Peng, Xiao-Rong and Guigas, Bruno and Boon, Mariëtte R and Wang, Yanan and Rensen, Patrick C N},
  title = {FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis},
  journal = {eLife},
  year = {2023},
  volume = {12},
  doi = {10.7554/elife.83075}
}
Kostenlos starten →